#Taipei #USA #Bioprocessing #Leadgene Biosolutions #BICO Group

Leadgene Biosolutions Rebranding

Leadgene Biosolutions, Inc., formerly known as CYTENA BPS, has recently announced a significant corporate rebranding that signals an exciting new phase of growth within the Leadgene Group. This strategic move comes after the company’s transition from the BICO Group, as it fully integrates with Leadgene Biomedical, a key player in the biotechnology sector specializing in the development of recombinant proteins, antibodies, and diagnostic reagents.

This merger provides Leadgene Biosolutions with an enhanced capacity to offer a comprehensive array of bioprocessing products and services suited for both research and industrial applications. The alignment between these two entities not only streamlines operations but also amplifies the innovative potential for groundbreaking bioprocessing advancements.

One of the highlights of this integration is Leadgene’s remarkable expansion into global bioprocessing and cell-based research markets. With a unified mission and vision, the company is keen on refining its existing technologies and developing new ones. Some of the primary platforms that Leadgene aims to continue advancing include its renowned microbioreactor systems: S.NEST®, C.NEST®, and C.BIRD™. These state-of-the-art solutions have gained recognition for being the only available options that provide true high-throughput culture capabilities, allowing users to perform both 24- and 96-well cultures efficiently.

The functionalities of these systems—such as adjustable mixing and integrated monitoring for dissolved oxygen (DO), pH levels, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR)—are fundamental to the organization’s overarching goals. Leadgene continues to focus on enhancing its long-term vision through the expansion of product families and applications geared towards more extensive bioprocessing workflows and detailed metabolic assays.

Cheng-Han (Charles) Tsai, CEO of Leadgene Biosolutions, expressed excitement about the company’s potential for growth: "Building on proven strengths in bioprocessing, the integration gives Leadgene Biosolutions the expanded expertise to advance our long-term plans with refined focus." Dr. Chasel Yung-Chun Chuang, Chairman of Leadgene Biomedical, remarked on the advantages of the integration, noting, "The group now delivers one of the most complete end-to-end bioprocessing ecosystems, enabling customers to move faster from early research to clinical-ready workflows."

As part of this transition, Leadgene Biosolutions assures its stakeholders that all existing contracts, demonstration schedules, warranties, and support services will remain intact and fully operational. Gradual updates to the branding and corporate identity will reflect a more cohesive and forward-looking vision that aligns with the group’s core values and aspirations.

For more information about Leadgene Biosolutions, visit their official website at Leadgene Biosolutions, and to learn more about Leadgene Biomedical, you can check Leadgene Biomedical.

In conclusion, the rebranding of Leadgene Biosolutions marks a pivotal moment in the company’s journey, paving the way for innovative developments in bioprocessing and reaffirming its commitment to enhancing scientific research and industrial applications through superior technology solutions. These changes are not only indicative of the company’s growth trajectory but serve as a testament to its ambition to lead in the ever-evolving biotechnology landscape.